Brief: Equillium Announces Initiation Of Phase 2 Study Of Eq101
10/11/2022 13:25
Nov 10 (Reuters) - Equillium Inc EQ.O :
* EQUILLIUM ANNOUNCES INITIATION OF PHASE 2 STUDY OF EQ101 A
FIRST-IN-CLASS MULTI-CYTOKINE INHIBITOR OF IL-2, IL-9 AND IL-15
TARGETING ALOPECIA AREATA
Source text for Eikon: ID:nBw2TCqmZa
Further company coverage: EQ.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Equillium
See all newsBrief: Equillium Receives Australian Regulatory Clearance To Initiate First-In-Human Clinical Trial Of Eq504
Equillium Inc reports results for the quarter ended June 30 - Earnings Summary
Equillium Q2 post narrower net loss than expected; starts R&D initiatives
Equillium Inc expected to post a loss of 5 cents a share - Earnings Preview
Equillium Q1 net loss, profit miss analyst expectations